BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh M, Kumar V, Sehrawat N, Yadav M, Chaudhary M, Upadhyay SK, Kumar S, Sharma V, Kumar S, Dilbaghi N, Sharma AK. Current paradigms in epigenetic anticancer therapeutics and future challenges. Semin Cancer Biol 2021:S1044-579X(21)00063-8. [PMID: 33766649 DOI: 10.1016/j.semcancer.2021.03.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther 2023;8:69. [PMID: 36797239 DOI: 10.1038/s41392-023-01341-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hui L, Ziyue Z, Chao L, Bin Y, Aoyu L, Haijing W. Epigenetic Regulations in Autoimmunity and Cancer: from Basic Science to Translational Medicine. Eur J Immunol 2023;:e2048980. [PMID: 36647268 DOI: 10.1002/eji.202048980] [Reference Citation Analysis]
3 Vignali V, Hines PA, Cruz AG, Ziętek B, Herold R. Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations. Front Med (Lausanne) 2022;9:1064003. [PMID: 36569125 DOI: 10.3389/fmed.2022.1064003] [Reference Citation Analysis]
4 Toma G, Karapetian E, Massa C, Quandt D, Seliger B. Characterization of the effect of histone deacetylation inhibitors on CD8(+) T cells in the context of aging. J Transl Med 2022;20:539. [PMID: 36419167 DOI: 10.1186/s12967-022-03733-9] [Reference Citation Analysis]
5 Sharma V, Sharma AK, Panwar A, Sheikh I, Sharma A, Dhir S, Dhama K, Thakur R. In-silico designing of an inhibitor against mTOR FRB domain: Therapeutic implications against breast cancer. J Exp Bio & Ag Sci 2022;10:1016-1023. [DOI: 10.18006/2022.10(5).1016.1023] [Reference Citation Analysis]
6 Raghav M, Sharma V, Gupta S, Kaushal A, Vashishth A, Tuli HS, Dhama K, Sharma A. In-silico designing of a potent ligand molecule against PTEN (Phosphatase and tensin homolog) implicated in Breast Cancer. J Exp Bio & Ag Sci 2022;10:840-845. [DOI: 10.18006/2022.10(4).840.845] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Jin Y, Liu T, Luo H, Liu Y, Liu D. Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development. Front Oncol 2022;12:848221. [PMID: 35419278 DOI: 10.3389/fonc.2022.848221] [Reference Citation Analysis]
8 Upadhyay SK, Kumar S, Rout C, Vashistha G, Aggarwal D. Risks and Concerns of Use of Nanoparticles in Agriculture. Sustainable Plant Nutrition in a Changing World 2022. [DOI: 10.1007/978-3-030-97389-6_16] [Reference Citation Analysis]
9 Ahmad A. Special Issue: Epigenetic regulation of cancer progression: Promises and progress. Semin Cancer Biol 2021:S1044-579X(21)00298-4. [PMID: 34921992 DOI: 10.1016/j.semcancer.2021.12.005] [Reference Citation Analysis]
10 Pant M, Dan S, Pant S, Raj A, Upadhyay SK. Progression in Alzheimer’s Disease Correlates With Epigenetics and Cerebral Formaldehyde: From Potential Hereditary Mechanism and Environmental Factors to Therapeutic Measures. Curr Pharmacol Rep 2021;7:187-205. [DOI: 10.1007/s40495-021-00265-6] [Reference Citation Analysis]
11 Fernandez A, O'Leary C, O'Byrne KJ, Burgess J, Richard DJ, Suraweera A. Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review. Front Mol Biosci 2021;8:685440. [PMID: 34307454 DOI: 10.3389/fmolb.2021.685440] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Mosca L, Vitiello F, Borzacchiello L, Coppola A, Tranchese RV, Pagano M, Caraglia M, Cacciapuoti G, Porcelli M. Mutual Correlation between Non-Coding RNA and S-Adenosylmethionine in Human Cancer: Roles and Therapeutic Opportunities. Cancers (Basel) 2021;13:3264. [PMID: 34209866 DOI: 10.3390/cancers13133264] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]